Fig. 4: YAP/TEAD inhibition by verteporfin reduces Lox expression and ECM crosslinking in fibrotic AT2 cells.

A Lox gene expression (n = 10 each) (*adjusted p < 0.05 considered significant with one-way ANOVA with Holm-Šídák’s multiple comparisons test). Mean ± s.d. PBS-veh vs. PBS-VP (p = 0.5039), p < 0.0001 for PBS-veh vs Bleo-veh, Bleo-veh vs. Bleo-VP (p = 0.400). B Immunoblotting of Lox protein on tissue homogenates of normal and fibrotic mouse lungs injected with VP in vivo, n = 3–4 as shown. C Representative immunofluorescence staining of Lox in tissue sections obtained from the same study described in (A) and (B) (Supplementary Fig. S2), scale bar: 50 um. (AF Autofluorescence). DLox gene expression. Mean ± s.d. *adjusted p < 0.05 considered significant with one-way ANOVA with repeated measures and pre-selected comparisons. Corrected for multiple comparisons using Holm-Šídák’s multiple comparisons test. PBS-veh vs. PBS-VP (p < 0.0001); PBS-veh vs Bleo-veh (p = 0.00009); Bleo-veh vs. Bleo-VP (0.0006). n = 4 independent isolations and E immunoblotting of Lox protein in supernatants of pmAT2 cells isolated from normal and fibrotic mice and treated with VP for 48 h, representative image, n = 4. Equal protein was loaded into each well and confirmed through the use of stain-free gels which label tryptophans. Source data for Panels (A, B, D and E) are provided as a Source Data file.